<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143713</url>
  </required_header>
  <id_info>
    <org_study_id>M12-821</org_study_id>
    <secondary_id>2013-001047-31</secondary_id>
    <nct_id>NCT02143713</nct_id>
  </id_info>
  <brief_title>Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain</brief_title>
  <official_title>Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study evaluating the continued safety and efficacy of elagolix in the
      management of moderate to severe endometriosis associated pain in adult pre-menopausal
      female subjects who completed 6 months treatment in Study M12-671.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Endometriosis-Associated Pain</measure>
    <time_frame>Month 6 of Treatment Period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of responders based on reduction from baseline in study M12-671 (NCT 01931670)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (DXA scan)</measure>
    <time_frame>Month 6 of Treatment Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in Study M12-671 (NCT 01931670)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transvaginal Ultrasound (TVU)</measure>
    <time_frame>Month 6 of Treatment Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change form Baseline in study M12-671 (NCT 01931670)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (DXA scan)</measure>
    <time_frame>Month 6 of Follow-up Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in Study M12-671 (NCT 01931670)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density (DXA scan)</measure>
    <time_frame>Month 12 of Follow-up Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in Study M12-671 (NCT01931670)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests (standard laboratory values including hormones)</measure>
    <time_frame>Month 6 of Treatment Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in Study M12-671 (NCT 01931670)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of study subjects with Adverse Events</measure>
    <time_frame>Up to Month 18</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests (standard laboratory values including hormones)</measure>
    <time_frame>Month 3 of Follow-up Period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from Baseline in Study M12-671 (NCT 01931670)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Elagolix Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix lower daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix higher dose twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>Two different doses with matching placebo (to maintain blind) daily in two different arms over a 6-Month Treatment Period</description>
    <arm_group_label>Elagolix Dose 1</arm_group_label>
    <arm_group_label>Elagolix Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has completed the 6-Month Treatment Period in pivotal study M12-671.

          -  Agrees to use required birth control methods during the study through Month 6 of the
             Post-treatment Follow-up period

        Exclusion Criteria:

          -  Clinically significant gynecological condition

          -  Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine,
             femoral neck or total hip

          -  Plans to become pregnant in the next 18 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W.Rachel  Duan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121963</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121939</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 121958</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea (DYS)</keyword>
  <keyword>Elagolix</keyword>
  <keyword>Non-menstrual Pelvic Pain (NMPP)</keyword>
  <keyword>Endometriosis-associated pain</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Gonadotropin-releasing Hormone Antagonist</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
